Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/23/2025

Inhaled Tobramycin vs. Colistin in Bronchiectasis: Guideline Recommendations

Cystic Fibrosis Bronchiectasis Guidelines

  • The Cystic Fibrosis Foundation strongly recommends inhaled tobramycin (Grade A recommendation) for CF patients 6 years and older with moderate to severe lung disease and persistent P. aeruginosa, based on substantial evidence showing improved lung function and reduced exacerbations 1
  • The Cystic Fibrosis Foundation recommends tobramycin (Grade B recommendation) to reduce exacerbations in CF patients with mild lung disease or who are asymptomatic 3
  • Comparative studies show tobramycin is superior to colistin in CF patients, with one study demonstrating tobramycin increased FEV1 by 6.7% while colistin showed no measured improvement in lung function 1
  • The Cystic Fibrosis Foundation explicitly states there is insufficient evidence to recommend colistin or other inhaled antibiotics (gentamicin, ceftazidime) for routine use in CF patients (Grade I recommendation) 1

Non-CF Bronchiectasis Guidelines

  • For non-CF bronchiectasis, the British Thoracic Society recommends inhaled colistin as first-line therapy for patients with chronic P. aeruginosa infection (Grade B recommendation) 2
  • The European Respiratory Society states there is insufficient evidence to recommend routine use of nebulized tobramycin in non-CF bronchiectasis, despite its clinical use in this population 4
  • Neither inhaled tobramycin nor colistin has FDA approval specifically for non-CF bronchiectasis treatment 2

Safety Considerations

  • Bronchospasm is a significant concern with inhaled antibiotics, particularly in non-CF bronchiectasis patients, with one study reporting wheezing in 50% of patients treated with inhaled tobramycin 2
  • Pre-treatment with bronchodilators is recommended to prevent bronchospasm with either medication 4

Treatment Approach Based on Current Evidence

  • For CF bronchiectasis: Inhaled tobramycin is the first-line therapy for patients with P. aeruginosa infection, administered intermittently (28 days on, 28 days off) 1
  • For non-CF bronchiectasis: Inhaled colistin is recommended as first-line therapy for patients with chronic P. aeruginosa infection who have frequent exacerbations 2
  • Regular monitoring through sputum cultures is essential with either medication to track bacterial density and development of resistance 4

REFERENCES

1

cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2007

2

cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2007

3

Inhaled Antibiotics for Non-Cystic Fibrosis Bronchiectasis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Inhaled Tobramycin Therapy [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025